

## SUPPLEMENTAL MATERIAL

Duong et al., <http://www.jem.org/cgi/content/full/jem.20131557/DC1>

Table S1 shows PHH donors' characteristics.

Table S2 shows CHC patients' characteristics.

Table S3 shows gene expression levels in non-HCV patients.

Table S4 shows primer sequences for qPCR.

Tables begin on next page.

**Table S1. PHH donors' characteristics**

Donor #	Gender	Age	Ethnicity	rs12979886	rs8099917	IFN- $\alpha$ 4h	IFN-AR1	STAT1	RSAD2
93	m	78	Caucasian	CT	TT	- +	0.0023 0.0030	0.0179 0.0628	0.0189 0.3154
117	f	38	Caucasian	CC	TT	- +	0.0011 0.0017	0.0088 0.0546	0.0009 0.1365
124	f	66	Caucasian	CT	TG	- +	0.0012 0.0060	0.0152 0.1343	0.0020 0.2930
125	f	48	Caucasian	CT	TG	- +	0.0016 0.0119	0.0398 0.2302	n.d n.d
127	f	68	Caucasian	CT	TT	- +	0.0005 0.0060	0.0254 0.1916	0.0024 0.5772
130	m	72	Caucasian	CC	TT	- +	0.0013 0.0046	0.0160 0.0682	0.0008 0.1107
134	f	44	Caucasian	CC	TT	- +	0.0008 0.0111	0.0324 0.3072	0.0018 0.5022
136	f	54	Caucasian	CT	TG	- +	0.0042 0.0083	0.0506 0.1063	0.0295 0.4000
139	f	44	African	CC	TT	- +	0.0008 0.0018	0.0312 0.1139	0.0040 0.3078
146	m	73	Caucasian	CC	TT	- +	0.0004 0.0018	0.0181 0.1010	0.0017 0.6848
156	m	78	Caucasian	CT	TT	- +	0.0007 0.0027	0.0425 0.1667	n.d n.d
160	f		Caucasian	CT	GG	- +	0.0017 0.0039	0.0097 0.0588	n.d n.d
163	m	58	Caucasian	CC	TT	- +	0.0004 0.0020	0.0172 0.0818	n.d n.d
165	m	72	Caucasian	CC	TT	- +	0.0005 0.0016	0.0346 0.1529	n.d n.d
167	f	55	Latin- American	CC	TT	- +	0.0010 0.0021	0.0179 0.1167	n.d n.d
184	m	76	Caucasian	CC	TT	- +	0.0008 0.0057	0.0327 0.0706	0.002777 0.243425
186	m	52	Caucasian	CC	TT	- +	0.0009 0.0046	0.0383 0.1450	0.005651 0.255957
188	f	48	Caucasian	CT	TG	- +	0.0008 0.0058	0.0208 0.0805	0.004918 0.245013
192	m	57	Caucasian	CT	TG	- +	0.0008 0.0028	0.0186 0.0841	0.003021 0.264701
193	m	56	Caucasian	CC	TT	- +	0.0008 0.0032	0.0367 0.1112	0.006815 0.314910
213	m	56	Caucasian	CT	TG	- +	0.0019 0.0095	0.0536 0.0905	0.027040 0.278948
216	m	68	Caucasian	TT	GG	- +	0.0015 0.0078	0.0567 0.1215	0.006750 0.177225
217	f	47	Caucasian	CC	TT	- +	0.0002 0.0024	0.0217 0.0594	0.000113 0.199586
220	m	70	Caucasian	CC	TT	- +	0.0006 0.0060	0.0087 0.0640	0.001626 0.380879
224	f	61	Caucasian	CC	TT	- +	0.0006 0.0048	0.0077 0.1367	0.000348 0.800981
228	m	62	Caucasian	CC	TT	- +	0.0005 0.0019	0.0178 0.0965	0.001315 0.203427
229	m	74	Caucasian	CT	TG	- +	0.0013 0.0144	0.0163 0.1267	0.001301 0.669947
230	f	61	Caucasian	CC	TT	- +	0.0006 0.0090	0.0195 0.1054	0.005474 0.469973
231	m	79	Caucasian	CT	TG	- +	0.0016 0.0199	0.0416 0.2186	n.d n.d
233	f	56	Caucasian	CT	GG	- +	0.0027 0.0272	0.0362 0.2070	n.d n.d

**Table S2. CHC patients' characteristics**

Patient #	Biopsy coding #	Gender	Age	HCV GT	Viral load	Clinical response	rs12979886	rs8099917
1	A478/B161	m	45	1	5632925	PNR	0	0
2	A502b	m	67	1b	2137002	No EoTR	1	1
3	A515	f	54	3a	75644	SVR	0	0
4	A518	m	48	4	45523	interrupted	2	2
5	A531	m	39	1a	3427262	no treatment	0	0
6	A532	m	55	1a	788024	no treatment	0	0
7	A544b	m	46	1a	1218968	no treatment	2	2
8	A551	m	46	1b	69000000	interrupted	0	0
9	A558c	f	47	1a	1444062	PNR	1	1
10	A563/A938	m	48	1b	713046	PNR	1	1
11	A566	m	42	1a	3556921	no treatment	1	1
12	A567	m	29	1b	384525	SVR	1	1
13	A574	m	43	1a	792776	no treatment	1	1
14	A582	m	35	1b	17594	SVR	0	0
15	A590	f	48	1a	3107291	No EoTR	0	0
16	A603	f	38	2	5780000	No EoTR	2	0
17	A622	f	48	4	88216	no treatment	2	2
18	A626	m	63	1	1752158	No EoTR	1	1
19	A643	f	52	2a/c	72157	Relapse	0	0
20	A650	f	44	3a	319000	SVR	1	1
21	A656	m	51	4e	864372	no treatment	1	1
22	A658	m	57	1	10327448	no treatment	1	1
23	A675	f	53	1	n.d.	no treatment	1	1
24	A687	f	69	1	1686605	no treatment	1	1
25	A688	f	48	3a	13538256	Relapse	1	0
26	A689	f	67	3a	265382	no treatment	1	1
27	A704	m	41	3a	15538256	SVR	0	0
28	A707	f	24	1b	440	SVR	0	0
29	A725	m	48	1a	36108528	PNR	1	0
30	A764	m	38	4	12000	SVR	0	0
31	A768	m	36	3a	1140000	EoTR	1	1
32	A770	m	49	4	165330	SVR	1	0
33	A795	m	54	1	222053	Breakthrough	0	0
34	A809	f	41	1a	4652760	PNR	1	1
35	A821	m	40	1a	15900000	Relapse	0	0
36	A847	m	49	4c	371535	Breakthrough	1	1
37	A864	f	50	3	1123718	Relapse	1	1
38	A865	m	35	1a	1578381	EoTR	1	0
39	A867	f	48	3a	28368	SVR	0	0
40	A897	f	34	1b	360000	Relapse	1	1
41	A931	f	49	4	4100000	no treatment	1	1
42	A940	m	50	3	2230542	SVR	0	0

Table S2

43	A942	m	42	1a	4291956	No EoTR	1	1
44	A954	m	44	1a	3884688	Relapse	1	1
45	A960	m	54	1a	4625025	no treatment	0	0
46	A962	m	53	1b	770000	Relapse	1	0
47	A998	m	51	1b	241223	Relapse	1	1
48	B007	m	37	3a	11426813	Relapse	0	0
49	B011	m	27	1b	3102	SVR	0	0
50	B020	m	43	1b	1089515	SVR	1	1
51	B022	m	35	4	4491065	SVR	0	0
52	B029	f	31	3a	249240	SVR	1	1
53	B061	f	44	1	90124	no treatment	1	1
54	B065	m	49	1a	1484271	Relapse	0	0
55	B078	m	55	3	578305	Relapse	1	0
56	B146	m	48	4b	3201553	PNR	2	0
57	B181	m	58	1b	57791	No EoTR	2	2
58	B261	f	40	1b	1145339	SVR	0	0
59	B271	f	52	1a	5800000	SVR	0	0
60	B292	m	60	1b	4326723	PNR	1	1
61	B293	m	55	1a	1710592	PNR	1	0
62	B357	f	51	1a	6487	SVR	1	1
63	B392	m	30	1a	1389686	no treatment	0	0
64	B411	f	53	2	7079458	SVR	1	0
65	B517	m	21	1	5011872	SVR	0	0
66	B523	f	55	1a	720851	SVR	1	0
67	B526	m	40	4	173269	interrupted	2	1
68	B528	m	44	1a	n.d.	no treatment	1	1
69	B585	f	51	3a	2398833	no treatment	0	0
70	B609	m	45	1a	7585775	SVR	1	1
71	B611	f	44	3a	11988	EoTR	1	0
72	B631	m	48	3a	2818383	no treatment	0	0
73	B636	m	51	1a	1202264	EoTR	0	0
74	B657	m	41	1a	270092	no treatment	1	2
75	B658	m	52	3a	6025596	no treatment	1	0
76	B659	m	49	4	3235937	no treatment	1	0
77	B669	m	47	4	139013	no treatment	1	1
78	B675	m	49	3a	672811	no treatment	1	0
79	B679	m	42	1a	n.d.	no treatment	0	0
80	B683	m	43	1a	n.d.	no treatment	1	1
81	B696	f	46	3	n.d.	no treatment	1	0
82	B723	m	59	1a	n.d.	no treatment	2	0
83	B728	m	37	1a	455164	ongoing	n.d.	n.d.
84	B736	m	43	1 a/b	941000	no treatment	0	0
85	B754	m	61	1a	n.d.	no treatment	0	0
86	B755	m	16	3a	3030490	no treatment	1	2
87	B757	m	43	3	1445439	no treatment	1	1

Table S2

88	B761	m	44	3a	1148154	EoTR	1	0
89	B768	m	51	1	5754399	no treatment	0	0
90	B769	m	59	4	26700	no treatment	1	0
91	B780	f	53	3a	n.d.	no treatment	1	1
92	B784	f	48	1a	n.d.	no treatment	1	1
93	B785	m	46	3a	1572883	no treatment	0	0
94	B786	m	47	3	474333	ongoing	2	1
95	B790	m	52	3a	2884032	no treatment	1	0
96	B798	f	45	3a	115079	no treatment	n.d.	n.d.
97	B805	m	41	1a	385577	no treatment	1	0
98	B806	f	47	1a	5815142	no treatment	1	1
99	B807	f	72	1b	530221	ongoing	2	2
100	B819	f	45	1b	2398832	no treatment	0	0
101	B822	m	59	1a	836996	no treatment	0	0
102	B823	m	49	4	3162278	no treatment	2	1
103	B825	m	45	1a	445108	ongoing	1	1
104	B827	m	15	1a	274768	no treatment	1	1
105	B834	f	47	1a	5998161	no treatment	1	0
106	B840	f	60	1b	1479108	no treatment	1	1
107	B851	m	61	1b	6309573444	ongoing	2	1
108	B855	m	44	1b	373837	n.a.	0	0
109	B856	m	24	1	64646	no treatment	2	2
110	B860	m	49	3a	806067	no treatment	1	1
111	B875	m	53	1b	2940128	no treatment	0	0
112	B876	f	61	1a	1348962	ongoing	1	0
113	B882	f	52	1a	1230268	no treatment	0	0
114	B887	m	58	1a	n.d.	n.a.	1	1
115	B888	m	49	1a	n.d.	no treatment	1	1
116	B890	m	51	1a	224979	no treatment	1	1
117	B893	m	52	3a	n.d.	n.a.	1	2
118	B903	m	19	3a	8509	no treatment	1	1
119	B916	m	36	3a	802225	no treatment	1	0
120	B918	m	56	1a	32800	treatment planned	1	0
121	B929	f	38	1a	112857	no treatment	0	0
122	B932	m	37	2	2818383	ongoing	0	0

n.d: not determined

n.a.= not available

rs12979886 (0=CC; 1=CT; 2=TT)

rs8099917 (0=TT; 1=TG; 2=GG)

shown in figure 7A

shown in figure 7B

SVR= Sustained virological response

EoTR= End of treatment response

PNR= primary non responder

**Table S3. Gene expression levels in non-HCV patients**

Patient #	Biopsy coding #	Gender	Age	Diagnosis	IFN-λR1	IFN-λ1	IFN-λ2/3
123	B447	m	31	Steatohepatitis	0.002689	n.d	n.d
124	B448	m	56	Steatosis	0.001848	n.d	n.d
125	B453	m	54	ALD	0.002212	n.d	n.d
126	B612	m	46	unclear hepatopathy	0.004467	und	und
127	B614	m	51	unclear hepatopathy	0.002765	und	und
128	B621	m	54	DILI	0.001397	und	und
129	B622	m	50	ASH/ NASH	0.001796	und	und
130	B627	m	60	ALD	0.001274	und	und
131	B632	m	73	NASH	0.002541	n.d	n.d
132	B633	m	61	ASH/ NASH	0.001660	und	und
133	B641	w	73	PBC	0.002373	n.d	n.d
134	B643	m	44	NAFLD	0.001547	und	und
135	B646	m	69	ALD with cirrhosis	0.000847	und	und
136	B652	w	39	normal liver	0.001393	und	und
137	B656	m	53	sclerotic hepatitis with cirrhosis	0.003741	und	und
138	B661	m	59	NAFLD	0.002330	n.d	n.d
139	B662	w	62	DILI	0.001800	und	und
140	B663	w	62	AIH	0.002538	und	und
141	B666	m	27	NAFLD	0.001699	und	und
142	B676	w	55	NASH	0.003754	n.d	n.d
143	B680	m	44	Steatosis, undetermined	0.005239	n.d	n.d
144	B686	m	78	DILI	0.001696	n.d	n.d
145	B700	m	39	NAFLD	0.003091	und	und
146	B705	m	61	NAFLD	0.003091	und	und
147	B707	w	75	ALD	0.000455	n.d	n.d
148	B717	w	39	DILI	0.002380	n.d	n.d
149	B718	m	42	unclear hepatopathy	0.003329	n.d	n.d
150	B720	m	34	NAFLD	0.004203	und	und
151	B725	w	49	NASH	0.002766	n.d	n.d
152	B731	m	67	unclear hepatopathy	0.004464	n.d	n.d
153	B734	m	40	NASH	0.002572	n.d	n.d
154	B735	w	73	NAFLD	0.003626	und	und
155	B745	w	59	unclear hepatopathy	0.005129	n.d	n.d
156	B746	w	53	unclear hepatopathy	0.006117	n.d	n.d
157	B747	m	65	NAFLD	0.002037	n.d	n.d
158	B762	m	54	Steatosis, undetermined	0.001320	n.d	n.d
159	B764	m	48	ALD	0.000757	n.d	n.d
160	B770	w	55	DILI	0.003574	n.d	n.d
161	B771	w	76	PBC	0.004478	n.d	n.d
162	B774	w	64	DILI	0.001913	n.d	n.d
163	B777	m	27	toxic hepatitis	0.001594	n.d	n.d
164	B779	w	56	NASH	0.001803	n.d	n.d
165	B782	w	84	unclear hepatopathy	0.001976	n.d	n.d
166	B787	m	33	ALD	0.002876	n.d	n.d
167	B791	w	67	PBC	0.004456	n.d	n.d
168	B795	m	71	NASH	0.001680	und	und
169	B797	m	65	ALD with cirrhosis	0.000978	und	und
170	B810	w	75	DILI	0.001749	und	und
171	B812	m	49	unclear hepatopathy	0.001950	n.d	n.d
172	B813	w	36	unclear hepatopathy	0.003455	und	und
173	B815	m	70	ALD	0.002705	und	und
174	B818	w	68	ALD with cirrhosis	0.000226	n.d	n.d
175	B821	m	64	ALD	0.001383	n.d	n.d

und: undetectable; n.d: not determined; DILI: drug induced liver injury; NASH: nonalcoholic steatohepatitis  
 AIH: autoimmune hepatitis; PBC: primary biliary cirrhosis; ASH: alcoholic steatohepatitis; ALD: alcoholic liver disease

**Table S4. Primer sequences for qPCR**

<b>Gene</b>	<b>Forward primer</b>	<b>Reverse primer</b>
GAPDH	5'-GCTCCTCCTGTTTCGACAGTCA-3'	5'-ACCTTCCCCATGGTGTCTGA-3'
IFN-λ1	5'-CACAGGAGCTAGCGAGCTTCA-3'	5'-TTTTCAGCTTGAGTGACTCTTCCA-3'
IFN-λ2/3	5'-GCCAAAGATGCCTTAGAAGAG-3'	5'-CAGAACCTTCAGCGTCAGG-3'
IFN-λR1	5'-CAGTGTCCCAGAAATACAGCA-3'	5'-TGTGTCCAGAAAAGTCCAGGGC-3'
ISG15	5'-TCCTGCTGGTGGTGACAA-3'	5'-TTGTTATTCCTCACCAGGATGCT-3'
RSAD2	5'-CTTTGTGCTGCCCTTGAG-3'	5'-CTTTGTGCTGCCCTTGAG-3'
STAT1	5'-TCCCCAGGCCCTTGTTG-3'	5'-CAAGCTGCTGAAGTTCGTACC-3'
USP18	5'-CTCAGTCCCGACGTGGAAC-3'	5'-ATCTCTCAAGCGCCATGCA-3'